Current methods of breast cancer detection do not meet the needs of all patients, particularly in women with abnormal or difficult-to-interpret imaging findings. Clinical examination and imaging technologies are critical elements for detecting and diagnosing breast cancer, yet the high rate of false positives and false negatives resulting from these approaches can significantly impact patient care. There is a clear need for an alternative approach to improve the accuracy of breast cancer detection when clinical assessment is challenging.
Videssa Breast is the first blood test of its kind to detect the presence or absence of breast cancer in women with abnormal or difficult-to-interpret mammographic findings. When used in combination with imaging, Videssa Breast can improve diagnostic accuracy and provide greater confidence and clarity when clinical assessment is challenging. Videssa Breast offers clarity for healthcare providers who must navigate complex decisions in women who present with difficult-to-interpret findings.
Find out why everyone is talking about Videssa Breast! Download our free eBook to learn more about an exciting new blood test that improves breast cancer detection.
Utilizing advanced proteomics technology, Provista Diagnostics has developed Videssa Breast, a simple blood test that detects and analyzes multiple tumor protein biomarkers for improved breast cancer detection. Unlike other blood-based technologies, such as, circulating tumor cells and cell-free DNA, breast cancer tumor proteins are well understood in the scientific literature and readily identified in the blood, offering a more effective approach to cancer detection.